Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

ImmunoGen stock

IMGN
US45253H1014
878613

Price

31.23
Today +/-
+0
Today %
+0 %

ImmunoGen stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ImmunoGen stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ImmunoGen stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ImmunoGen stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ImmunoGen's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ImmunoGen Stock Price History

DateImmunoGen Price
2/13/202431.23 undefined
2/12/202431.23 undefined

ImmunoGen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ImmunoGen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ImmunoGen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ImmunoGen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ImmunoGen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ImmunoGen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ImmunoGen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ImmunoGen’s growth potential.

ImmunoGen Revenue, EBIT and net profit per share

DateImmunoGen RevenueImmunoGen EBITImmunoGen Net Income
2029e1.3 B undefined700.5 M undefined549.93 M undefined
2028e1.32 B undefined734.1 M undefined595.52 M undefined
2027e1.22 B undefined615.47 M undefined530.92 M undefined
2026e1.03 B undefined466.61 M undefined403.39 M undefined
2025e794.2 M undefined277.81 M undefined244.57 M undefined
2024e560.86 M undefined116.72 M undefined107.05 M undefined
2023e384.16 M undefined15.27 M undefined21.57 M undefined
2022108.8 M undefined-220.9 M undefined-222.9 M undefined
202169.9 M undefined-125.1 M undefined-139.3 M undefined
2020132.3 M undefined-20.9 M undefined-44.4 M undefined
201982.3 M undefined-70.8 M undefined-104.1 M undefined
201853.4 M undefined-157.7 M undefined-168.8 M undefined
2017115.4 M undefined-58.2 M undefined-96 M undefined
201660 M undefined-125 M undefined-144.8 M undefined
201585.5 M undefined-54.5 M undefined-60.7 M undefined
201459.9 M undefined-71.5 M undefined-71.4 M undefined
201335.5 M undefined-73 M undefined-72.8 M undefined
201216.4 M undefined-73.3 M undefined-73.3 M undefined
201119.3 M undefined-60.2 M undefined-58.3 M undefined
201013.9 M undefined-51.2 M undefined-50.9 M undefined
200928 M undefined-31.8 M undefined-31.9 M undefined
200840.2 M undefined-34.1 M undefined-32 M undefined
200738.2 M undefined-22.2 M undefined-19 M undefined
200632.1 M undefined-21.4 M undefined-17.8 M undefined
200535.7 M undefined-12.7 M undefined-11 M undefined
200426 M undefined-8.4 M undefined-5.9 M undefined
20037.6 M undefined-24.6 M undefined-20 M undefined

ImmunoGen Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e2029e
000000000000000.0100.010.010.030.040.030.040.040.030.010.020.020.040.060.090.060.120.050.080.130.070.110.380.560.791.031.221.321.3
-----200.00-33.33-50.00------266.67-63.6425.0040.00271.4334.62-8.5718.755.26-30.00-53.5746.15-15.79118.7568.5744.07-29.4191.67-53.9154.7260.98-47.7356.52255.5645.8341.7929.4718.688.20-1.36
----10,800.003,600.005,400.0010,800.00-----100.00100.0075.0040.0057.1476.9274.2990.63284.21270.00385.71830.77568.42675.00308.57183.05127.06180.0093.91203.77131.7181.82156.52100.0028.1319.2913.6010.518.858.188.29
00000000000003113242026290000000000000001080000000
-1-1-3-5-8-8-15-18-23-19-18-12-8-50-15-14-20-5-11-17-19-32-31-50-58-73-72-71-60-144-96-168-104-44-139-22221107244403530595549
--200.0066.6760.00-87.5020.0027.78-17.39-5.26-33.33-33.33-37.50---6.6742.86-75.00120.0054.5511.7668.42-3.1361.2916.0025.86-1.37-1.39-15.49140.00-33.3375.00-38.10-57.69215.9159.71-109.46409.52128.0465.1631.5112.26-7.73
2.92.93.34.45.76.99.710.611.312.614.417.924.225.529.536.739.641.940.640.941.241.84351.158.868.976.884.185.5868798.1139.9148.3176.2206.1253.60000000
--------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The ImmunoGen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ImmunoGen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                                                     
7.211.64157.634.421.232.81.71.74.217.394.5137.8101.394.690.67559.747.971.1110.3191.2160.9195142.3278.1245160267.1262.3176.2293.9478.8275.1
0000000000.90.900.72.50.810.56.577.53.92.33.46.21.32.13.25.82.38.85.22.812.109.814.1
000000000.310.400000000000000000009.315.122.54.13.9
0000000000002.22.95.66.61.51.23.32.11.81.20.51.30.732.90.92.2100000
0.10.10.20.40.60.60.30.20.20.10.10.42.22.110.81.41.31.72.21.62.23.72.72.92.35.44.95.434.55.47.97.311
7.311.741.2583521.83.332.23.75.617.799.6145.3108.7112.510084.572.256.176.8117.1201.6166.2200.7150.8292.2253.1176.4276.3278.9208.8324.3500304.1
1.83.43.1410.916.513.64.22.91.91.61.53.26.799.79.99.38.122.819.716.313.411.610.814.316.322.719.514.512.922.619.817.114.6
00000000000056.30000000000000000000000
00000001.31.10.30000000000000000000000000
00000000000000000000000000000000000
00000000000000000000000000000000000
000.10.10.50.10.100000000.30.30.30.30.24.54.23.82.72.42.10.25.43.433.83.73.8118.730.2
1.83.43.24.111.416.613.75.542.21.61.559.56.79.31010.29.68.327.323.920.116.11412.914.521.726.122.518.316.626.430.825.844.8
9.115.144.462.146.438.4178.56.25.97.219.2159.1152118122.5110.294.180.583.4100.7137.2217.7180.2213.6165.3313.9279.2198.9294.6295.5235.2355.1525.8348.9
                                                                     
00.10.10.10.10.10.10.20.20.30.30.30.40.40.40.40.40.40.40.50.60.70.80.80.80.90.90.90.91.31.51.522.22.3
0.020.030.070.110.110.120.120.130.140.150.160.170.310.320.320.320.320.310.320.340.390.470.570.590.70.720.740.770.781.011.191.211.421.791.85
-14.3-22.7-31.5-46.8-65.4-89.1-109-127.9-140.5-148.7-153.7-154-169.2-183.9-203.9-209.8-220.7-238.6-257.5-289.6-321.5-372.4-430.6-504-576.8-648.1-708.9-853.7-932.6-1,028.6-1,183.3-1,287.5-1,331.8-1,471.1-1,694.1
00000000000300300600100-200-100-400-100-100-2003000000000000000
00000000000000000000000000000000000
712.24259.140.63010.10.84.54.45.415.3142.5134.2113.7108.197.972.358.455.366.8102.114083.9121.875.835.1-82.3-152.9-17.911-76.289.7325.6155.8
1.11.61.31.52.82.22.20.70.60.70.90.90.80.61.12.12.11.32.21.41.23.13.23.44.54.88.111.57.98.611.49.99.518.445.4
0.10.40.40.81.71.91.31.11.10.80.81.233.71.81.92.14.15.75.55.76.689.512.213.518.820.418.127.232.325.937.132.154
000000000000.31.62.22.87.25.15.36.43.54.24.23.33.32.52.98.928.529.8202741.673.644.413.9
00000000000000000000000000000000000
0.10.10.10.10.20.80.90.10.10.10.10.1000000000000000000002.16.18.7
1.32.11.82.44.74.94.41.91.81.61.82.55.46.55.711.29.310.714.310.411.113.914.516.219.221.235.860.455.855.870.777.4122.3101122
0.80.70.60.61.23.32.35.8000.1000000000000000096.6972.12.184.341.13523.4
00000000000000000000000000000000000
000000.20.100.1001.511.411.49.714.214.111.17.717.722.721.363.180.272.668.4242.9204.5199254.8211.7149.6102.164.347.8
0.80.70.60.61.23.52.45.80.100.11.511.411.49.714.214.111.17.717.722.721.363.180.272.668.4242.9301.1296256.9213.8233.9143.299.371.2
2.12.82.435.98.46.87.71.91.61.9416.817.915.425.423.421.82228.133.835.277.696.491.889.6278.7361.5351.8312.7284.5311.3265.5200.3193.2
9.11544.462.146.538.416.98.56.467.319.3159.3152.1129.1133.5121.394.180.483.4100.6137.3217.6180.3213.6165.4313.8279.2198.9294.8295.5235.1355.2525.9349
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ImmunoGen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ImmunoGen's financial health and stability.

Assets

ImmunoGen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ImmunoGen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ImmunoGen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ImmunoGen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162016201720182019202020212022
-3-3-5-8-8-15-18-23-19-18-12-8-40-15-14-19-5-10-17-18-32-31-50-58-73-72-71-60-144-78-96-168-104-44-139-222
0000111232110000112234544444553574221
0000000000000000000000000000000000000
000000100100012-1-206-1-23814125-4-16-15-2-1377025-4-23-25
000000000531005000022698101925453139531120-17842
0000000000000000000000000000000400000
0000000000000000000000000000000000000
-2-2-4-6-8-13-15-21-16-8-7-5-32-6-16-21-5-2-14-15-20-13-40-7-34-60-53-55-124-837-166-88-78-169-229
000-20-2-8-7000000-2-4-3-1-2-2-1-18-1-1-2-2-3-8-7-10-1-1-5-20-1-1
000-5-233-13-2190000-15-12211261-11419151200-2-3-8-7-10-1-1-500-1-1
000-2-225-55190000-15-1191530301621331301000000002100
0000000000000000000000000000000000000
0000000-10800000000000000000009600000-10
44913383201300755101426-110012263980906989450102166219515727
44913383201508655101426-1100122639809069891981010100166219535527
000000040000000000000000000019400-10001990
0000000000000000000000000000000000000
1131721-28-710-102-2131-6-3-31521383982-3034-52135-33-85107-4-86117184-203
-3.2-3.2-5.38-9.12-9.06-15.81-23.62-29.1-17.22-8.65-8.04-6-3.661.95-8.9-20.26-25.54-6.98-4.51-16.41-17.76-38.15-15.23-42.11-10.02-37.2-64.07-61.83-62.72-134.86-85.076.53-171.67-91.22-79.54-170.85-231.16
0000000000000000000000000000000000000

ImmunoGen stock margins

The ImmunoGen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImmunoGen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImmunoGen.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ImmunoGen's sales revenue. A higher gross margin percentage indicates that the ImmunoGen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ImmunoGen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ImmunoGen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ImmunoGen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ImmunoGen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ImmunoGen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ImmunoGen Margin History

ImmunoGen Gross marginImmunoGen Profit marginImmunoGen EBIT marginImmunoGen Profit margin
2029e99.82 %53.8 %42.24 %
2028e99.82 %55.57 %45.08 %
2027e99.82 %50.45 %43.52 %
2026e99.82 %45.39 %39.24 %
2025e99.82 %34.98 %30.79 %
2024e99.82 %20.81 %19.09 %
2023e99.82 %3.98 %5.62 %
202299.82 %-203.03 %-204.87 %
202199.82 %-178.97 %-199.28 %
202099.82 %-15.8 %-33.56 %
201999.82 %-86.03 %-126.49 %
201899.82 %-295.32 %-316.1 %
201799.82 %-50.43 %-83.19 %
201699.82 %-208.33 %-241.33 %
201599.82 %-63.74 %-70.99 %
201499.82 %-119.37 %-119.2 %
201399.82 %-205.63 %-205.07 %
201299.82 %-446.95 %-446.95 %
201199.82 %-311.92 %-302.07 %
201099.82 %-368.35 %-366.19 %
200999.82 %-113.57 %-113.93 %
200899.82 %-84.83 %-79.6 %
200799.82 %-58.12 %-49.74 %
200691.59 %-66.67 %-55.45 %
200574.23 %-35.57 %-30.81 %
200478.08 %-32.31 %-22.69 %
200363.16 %-323.68 %-263.16 %

ImmunoGen Stock Sales Revenue, EBIT, Earnings per Share

The ImmunoGen earnings per share therefore indicates how much revenue ImmunoGen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ImmunoGen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ImmunoGen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ImmunoGen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ImmunoGen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ImmunoGen Revenue, EBIT and net profit per share

DateImmunoGen Sales per ShareImmunoGen EBIT per shareImmunoGen Earnings per Share
2029e4.66 undefined0 undefined1.97 undefined
2028e4.73 undefined0 undefined2.13 undefined
2027e4.37 undefined0 undefined1.9 undefined
2026e3.68 undefined0 undefined1.44 undefined
2025e2.84 undefined0 undefined0.88 undefined
2024e2.01 undefined0 undefined0.38 undefined
2023e1.38 undefined0 undefined0.08 undefined
20220.43 undefined-0.87 undefined-0.88 undefined
20210.34 undefined-0.61 undefined-0.68 undefined
20200.75 undefined-0.12 undefined-0.25 undefined
20190.55 undefined-0.48 undefined-0.7 undefined
20180.38 undefined-1.13 undefined-1.21 undefined
20171.18 undefined-0.59 undefined-0.98 undefined
20160.69 undefined-1.44 undefined-1.66 undefined
20150.99 undefined-0.63 undefined-0.71 undefined
20140.7 undefined-0.84 undefined-0.84 undefined
20130.42 undefined-0.87 undefined-0.87 undefined
20120.21 undefined-0.95 undefined-0.95 undefined
20110.28 undefined-0.87 undefined-0.85 undefined
20100.24 undefined-0.87 undefined-0.87 undefined
20090.55 undefined-0.62 undefined-0.62 undefined
20080.93 undefined-0.79 undefined-0.74 undefined
20070.91 undefined-0.53 undefined-0.45 undefined
20060.78 undefined-0.52 undefined-0.43 undefined
20050.87 undefined-0.31 undefined-0.27 undefined
20040.64 undefined-0.21 undefined-0.15 undefined
20030.18 undefined-0.59 undefined-0.48 undefined

ImmunoGen business model

ImmunoGen Inc is a leading company in the biotechnology industry. The company was founded in 1981 as a research facility. In recent decades, ImmunoGen Inc has specialized in the development of antibody-drug conjugates (ADCs). ADCs are drugs that consist of an antibody and a cytotoxin that specifically targets tumor cells. In this way, cancer cells can be selectively destroyed without damaging surrounding tissue. ImmunoGen Inc has achieved success in recent years, particularly in the development of ADCs against serious cancers such as lung cancer or breast cancer, and it also collaborates with major pharmaceutical companies such as Roche or Bayer. The business model of ImmunoGen Inc, therefore, consists of developing innovative cancer drugs and successfully bringing them to market. Another branch of the company is the development of therapeutics for other diseases such as rheumatoid arthritis or multiple sclerosis. ImmunoGen Inc also utilizes ADCs to selectively destroy disease-specific cells in these cases. In the past, ImmunoGen Inc has successfully launched several products on the market. For example, in 2019, the cancer drug Kadcyla, manufactured by Roche and based on ImmunoGen's ADC technology, was approved by the US Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. The ADC development candidate IMGN632 also shows promising results in the treatment of acute myeloid leukemia and other cancer diseases. The history of ImmunoGen Inc has also been marked by some challenges. In the early years of the company, it faced financial difficulties and sold a large number of shares to an investor in 1999. However, the company remained diligent in research and development and eventually became one of the leading biotech companies in the field of cancer research with the development of ADCs. Nevertheless, the company has also experienced setbacks in the development of products and has had to discontinue several development programs. Despite everything, ImmunoGen Inc is considered a successful company in the biotechnology industry, effectively marketing its innovative solutions in the oncology market. It is also being closely watched to see whether future ADCs will not have to undergo as long development cycles as their predecessors, which can guarantee long-term success for the company. ImmunoGen is one of the most popular companies on Eulerpool.com.

ImmunoGen SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ImmunoGen Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ImmunoGen historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ImmunoGen shares outstanding

The number of shares was ImmunoGen in 2023 — This indicates how many shares 253.6 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ImmunoGen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ImmunoGen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ImmunoGen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ImmunoGen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for ImmunoGen.

ImmunoGen latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20230.05 0.1  (119.78 %)2023 Q3
6/30/2023-0.14 -0.02  (85.92 %)2023 Q2
3/31/2023-0.25 -0.16  (37.06 %)2023 Q1
12/31/2022-0.3 -0.23  (23.99 %)2022 Q4
9/30/2022-0.26 -0.31  (-19.41 %)2022 Q3
6/30/2022-0.22 -0.24  (-11.01 %)2022 Q2
3/31/2022-0.22 -0.1  (53.53 %)2022 Q1
12/31/2021-1.74 -0.17  (90.24 %)2021 Q4
9/30/2021-0.19 -0.18  (4.31 %)2021 Q3
6/30/2021-0.19 -0.15  (19.31 %)2021 Q2
1
2
3

Eulerpool ESG Scorecard© for the ImmunoGen stock

Eulerpool World ESG Rating (EESG©)

60/ 100

🌱 Environment

67

👫 Social

44

🏛️ Governance

68

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ImmunoGen shareholders

%
Name
Stocks
Change
Date
9.09912 % The Vanguard Group, Inc.25,418,388979,85712/31/2023
8.50209 % RA Capital Management, LP23,750,60110,428,31312/31/2023
6.67502 % BlackRock Institutional Trust Company, N.A.18,646,6791,793,78612/31/2023
5.87933 % Redmile Group, LLC16,423,922-1,079,49512/31/2023
3.95346 % Janus Henderson Investors11,043,986-6,640,83012/31/2023
2.89088 % State Street Global Advisors (US)8,075,671-1,476,18112/31/2023
2.12264 % Fairmount Funds Management LLC5,929,592012/31/2023
2.02703 % Pentwater Capital Management LP5,662,5005,662,50012/31/2023
1.98294 % Norges Bank Investment Management (NBIM)5,539,3345,424,43412/31/2023
1.92693 % Geode Capital Management, L.L.C.5,382,875482,90012/31/2023
1
2
3
4
5
...
10

ImmunoGen Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
MacroGenics Stock
MacroGenics
SupplierCustomer0,930,900,810,930,550,28
Bayer Stock
Bayer
SupplierCustomer0,880,86-0,23-0,73-0,63-0,38
CytomX Therapeutics Stock
CytomX Therapeutics
SupplierCustomer0,840,270,600,730,590,41
Novartis Stock
Novartis
SupplierCustomer0,810,74-0,44-0,70-0,38-0,06
Roche Holding Stock
Roche Holding
SupplierCustomer0,740,920,140,29 -0,33
Fusion Pharmaceuticals Stock
Fusion Pharmaceuticals
SupplierCustomer0,240,960,68-0,090,09-0,03
Eli Lilly Stock
Eli Lilly
SupplierCustomer-0,03-0,20-0,25-0,43-0,47
Viridian Therapeutics Stock
Viridian Therapeutics
SupplierCustomer-0,14-0,080,530,660,410,43
Amgen Stock
Amgen
SupplierCustomer-0,47-0,88-0,10-0,58-0,29-0,10
Huadong Medicine A Stock
Huadong Medicine A
SupplierCustomer-0,60-0,660,080,340,290,20
1

Most common questions regarding ImmunoGen

What values and corporate philosophy does ImmunoGen represent?

ImmunoGen Inc represents values of innovation, dedication, and patient-centricity. With a strong corporate philosophy focused on developing targeted cancer therapies, ImmunoGen is committed to improving the lives of patients battling cancer. By harnessing the power of its unique Antibody-Drug Conjugate (ADC) technology, ImmunoGen strives to deliver transformative treatments that specifically target cancer cells while sparing healthy cells. The company's dedication to research, collaboration, and delivering breakthrough therapies sets it apart in the biotechnology industry. ImmunoGen Inc prioritizes patient well-being and relentlessly pursues advancements in precision medicine to shape the future of cancer treatment.

In which countries and regions is ImmunoGen primarily present?

ImmunoGen Inc, a leading biotechnology company, primarily operates in the United States. With its headquarters located in Waltham, Massachusetts, ImmunoGen Inc primarily focuses on the development and commercialization of innovative antibody-drug conjugate (ADC) therapies for the treatment of various types of cancer. By leveraging its proprietary technology platform, ImmunoGen Inc has gained recognition and presence in the US healthcare industry. As a US-based company, ImmunoGen Inc has been actively involved in collaborations and partnerships with other biopharmaceutical companies to expand its global reach and potentially introduce its revolutionary ADC therapies to patients worldwide.

What significant milestones has the company ImmunoGen achieved?

ImmunoGen Inc has achieved several significant milestones. The company successfully developed and obtained FDA approval for its targeted anti-cancer therapy, Kadcyla. This milestone revolutionized the treatment of HER2-positive breast cancer, providing a more effective and less toxic treatment option. ImmunoGen Inc also partnered with leading pharmaceutical companies like Roche, Amgen, and Takeda, further validating their novel technology platform. Additionally, the company has made notable progress in advancing their pipeline candidates, including IMGN632 and IMGN151, targeting various hematological malignancies. These achievements demonstrate ImmunoGen Inc's commitment to groundbreaking research and the potential to significantly impact cancer treatment.

What is the history and background of the company ImmunoGen?

ImmunoGen Inc is a pharmaceutical company founded in 1981 and headquartered in Waltham, Massachusetts. With a focus on developing targeted antibody-drug conjugates (ADCs), ImmunoGen has been a pioneer in the field of cancer therapeutics. The company's innovative technology aims to deliver treatment directly to cancer cells while minimizing damage to healthy cells. ImmunoGen has partnered with various pharmaceutical companies to accelerate the development and commercialization of ADCs. Over the years, ImmunoGen has gained recognition for its expertise in ADC research and continues to advance its pipeline of novel therapies, making significant contributions to the field of oncology.

Who are the main competitors of ImmunoGen in the market?

The main competitors of ImmunoGen Inc in the market include pharmaceutical companies such as Roche Holding AG, Pfizer Inc, and Bristol-Myers Squibb Company.

In which industries is ImmunoGen primarily active?

ImmunoGen Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of ImmunoGen?

The business model of ImmunoGen Inc is focused on the development of targeted antibody-drug conjugates (ADCs) for the treatment of cancer. ADCs leverage the specificity of antibodies to selectively deliver potent cytotoxic drugs to cancer cells, aiming to minimize side effects. ImmunoGen's proprietary technology, known as ADC technology, involves the use of monoclonal antibodies that target specific proteins overexpressed on cancer cells. These antibodies are conjugated with cytotoxic agents to create ADCs, which bind to cancer cells, allowing for targeted delivery of the drug payload. By advancing its technology and collaborations, ImmunoGen aims to provide innovative treatment options for patients with cancer.

What is the P/E ratio of ImmunoGen 2024?

The ImmunoGen P/E ratio is 73.98.

What is the P/S ratio of ImmunoGen 2024?

The ImmunoGen P/S ratio is 14.12.

What is the Quality Investing of ImmunoGen?

The Quality Investing for ImmunoGen is 6/10.

What is the revenue of ImmunoGen 2024?

The expected ImmunoGen revenue is 560.86 M USD.

How high is the profit of ImmunoGen 2024?

The expected ImmunoGen profit is 107.05 M USD.

What is the business model of ImmunoGen

ImmunoGen Inc is a biotechnology company specializing in the development of innovative therapy approaches for the treatment of cancer. The company's business model is based on the discovery and development of drugs that selectively destroy cancer cells while sparing the surrounding healthy tissue. ImmunoGen utilizes its own technology platform called Antibody-Drug Conjugates (ADCs) for this purpose. ADCs are a new class of drugs that can target cancer cells specifically. They consist of three components: an antibody that binds specifically to cancer cells, a drug that kills the cancer cells, and a linker that connects the two components. By combining these components, ADCs enable targeted tumor destruction and reduce the burden on healthy tissue. ImmunoGen's flagship product is the ADC candidate Mirvetuximab Soravtansine, which is currently being tested in Phase 3 clinical trials for the treatment of ovarian cancer. Mirvetuximab Soravtansine has higher efficacy and fewer side effects compared to conventional chemotherapeutics. In addition, ImmunoGen is developing other ADC candidates in various stages of clinical development. In addition to ADC development, ImmunoGen also operates a service business focused on the manufacturing and optimization of ADCs for other pharmaceutical companies. ImmunoGen has extensive experience in ADC manufacturing and offers this expertise as a service. Furthermore, ImmunoGen collaborates with other companies and research institutions to further develop and expand the ADC technology platform. Another business area of ImmunoGen is the research and development of new technology platforms. The company continuously invests in the exploration of new approaches for cancer therapy. This includes the ABC technology platform, which aims to improve the short-term stability of ADCs while increasing their efficacy. ImmunoGen aims to become a leading biotechnology company in the field of cancer therapy. With its innovative ADC technology platform and the development of promising candidates like Mirvetuximab Soravtansine, ImmunoGen is on track to achieve this goal. With a broad portfolio of products and services, ImmunoGen is well-equipped to withstand an increasingly complex and volatile industry.

What is the ImmunoGen dividend?

ImmunoGen pays a dividend of 0 USD distributed over payouts per year.

How often does ImmunoGen pay dividends?

The dividend cannot currently be calculated for ImmunoGen or the company does not pay out a dividend.

What is the ImmunoGen ISIN?

The ISIN of ImmunoGen is US45253H1014.

What is the ImmunoGen WKN?

The WKN of ImmunoGen is 878613.

What is the ImmunoGen ticker?

The ticker of ImmunoGen is IMGN.

How much dividend does ImmunoGen pay?

Over the past 12 months, ImmunoGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmunoGen is expected to pay a dividend of 0 USD.

What is the dividend yield of ImmunoGen?

The current dividend yield of ImmunoGen is .

When does ImmunoGen pay dividends?

ImmunoGen pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ImmunoGen?

ImmunoGen paid dividends every year for the past 0 years.

What is the dividend of ImmunoGen?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ImmunoGen located?

ImmunoGen is assigned to the 'Health' sector.

Wann musste ich die Aktien von ImmunoGen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ImmunoGen from 12/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/6/2024.

When did ImmunoGen pay the last dividend?

The last dividend was paid out on 12/6/2024.

What was the dividend of ImmunoGen in the year 2023?

In the year 2023, ImmunoGen distributed 0 USD as dividends.

In which currency does ImmunoGen pay out the dividend?

The dividends of ImmunoGen are distributed in USD.

All fundamentals about ImmunoGen

Our stock analysis for ImmunoGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmunoGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.